Fate Therapeutics, Inc. (FATE)

$19.1

-0.04 (-0.21%)
Rating:
Recommendation:
Neutral
Symbol FATE
Price $19.1
Beta 1.574
Volume Avg. 1.29M
Market Cap 1.856B
Shares () -
52 Week Range 17.1-66.56
1y Target Est -
DCF Unlevered FATE DCF ->
DCF Levered FATE LDCF ->
ROE -48.78% Strong Sell
ROA -39.23% Strong Sell
Operating Margin -
Debt / Equity 44.66% Neutral
P/E -7.83 Strong Sell
P/B 3.58 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest FATE news


Mr. John Wolchko
Healthcare
Biotechnology
NASDAQ Global Market

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.